1. Home
  2. AVDL vs NEXA Comparison

AVDL vs NEXA Comparison

Compare AVDL & NEXA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVDL
  • NEXA
  • Stock Information
  • Founded
  • AVDL 2015
  • NEXA 1956
  • Country
  • AVDL Ireland
  • NEXA Luxembourg
  • Employees
  • AVDL N/A
  • NEXA N/A
  • Industry
  • AVDL Biotechnology: Pharmaceutical Preparations
  • NEXA Metal Mining
  • Sector
  • AVDL Health Care
  • NEXA Basic Materials
  • Exchange
  • AVDL Nasdaq
  • NEXA Nasdaq
  • Market Cap
  • AVDL 784.6M
  • NEXA 660.9M
  • IPO Year
  • AVDL 1996
  • NEXA 2017
  • Fundamental
  • Price
  • AVDL $9.18
  • NEXA $4.68
  • Analyst Decision
  • AVDL Strong Buy
  • NEXA Sell
  • Analyst Count
  • AVDL 6
  • NEXA 3
  • Target Price
  • AVDL $18.17
  • NEXA $6.33
  • AVG Volume (30 Days)
  • AVDL 1.3M
  • NEXA 35.8K
  • Earning Date
  • AVDL 08-07-2025
  • NEXA 07-31-2025
  • Dividend Yield
  • AVDL N/A
  • NEXA 2.15%
  • EPS Growth
  • AVDL N/A
  • NEXA N/A
  • EPS
  • AVDL N/A
  • NEXA N/A
  • Revenue
  • AVDL $194,450,000.00
  • NEXA $2,813,814,000.00
  • Revenue This Year
  • AVDL $56.88
  • NEXA N/A
  • Revenue Next Year
  • AVDL $29.81
  • NEXA $3.43
  • P/E Ratio
  • AVDL N/A
  • NEXA N/A
  • Revenue Growth
  • AVDL 252.64
  • NEXA 13.20
  • 52 Week Low
  • AVDL $6.38
  • NEXA $4.64
  • 52 Week High
  • AVDL $17.30
  • NEXA $9.61
  • Technical
  • Relative Strength Index (RSI)
  • AVDL 47.63
  • NEXA 30.66
  • Support Level
  • AVDL $9.10
  • NEXA $4.84
  • Resistance Level
  • AVDL $9.76
  • NEXA $5.00
  • Average True Range (ATR)
  • AVDL 0.47
  • NEXA 0.16
  • MACD
  • AVDL -0.08
  • NEXA 0.01
  • Stochastic Oscillator
  • AVDL 14.29
  • NEXA 7.84

About AVDL Avadel Pharmaceuticals plc

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.

About NEXA Nexa Resources S.A.

Nexa Resources SA is a low-cost integrated zinc producer. It produces copper, silver, and gold as byproducts. The company operates through two segments namely Mining and Smelting. Its Mining segment consists of various operating units includes mineral exploration activities and the production of zinc concentrates, copper concentrates and concentrates. The Smelting segment comprises operating units which include facilities recovering and refining zinc metal out of feed materials such as zinc concentrates or secondary feed materials. It generates maximum revenue from the Smelting segment. Geographically It has a presence in Brazil, Peru, the United States of America, Switzerland, Japan, Argentina, South Korea, Colombia, Vietnam, Malaysia and other countries.

Share on Social Networks: